Cantargia AB (publ) Logo

Cantargia AB (publ)

CANTA.ST

(1.5)
Stock Price

3,80 SEK

-79.18% ROA

-120.03% ROE

-1.87x PER

Market Cap.

589.467.640,00 SEK

0% DER

0% Yield

0% NPM

Cantargia AB (publ) Stock Analysis

Cantargia AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cantargia AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (2.02x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

4 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

5 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

6 ROE

The stock's ROE indicates a negative return (-84.56%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-79.18%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Cantargia AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cantargia AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Cantargia AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cantargia AB (publ) Revenue
Year Revenue Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cantargia AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 76.951.000 100%
2019 97.477.000 21.06%
2020 158.396.000 38.46%
2021 352.709.000 55.09%
2022 364.686.000 3.28%
2023 301.100.000 -21.12%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cantargia AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 513.440
2012 529.969 3.12%
2013 2.069.059 74.39%
2014 3.207.760 35.5%
2015 4.953.000 35.24%
2016 5.119.000 3.24%
2017 6.917.000 25.99%
2018 15.823.000 56.29%
2019 13.097.000 -20.81%
2020 14.919.000 12.21%
2021 15.309.000 2.55%
2022 14.964.000 -2.31%
2023 13.220.000 -13.19%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cantargia AB (publ) EBITDA
Year EBITDA Growth
2011 -3.385.815
2012 -3.465.168 2.29%
2013 -7.945.937 56.39%
2014 -8.117.618 2.11%
2015 -16.995.000 52.24%
2016 -44.615.000 61.91%
2017 -60.264.000 25.97%
2018 -91.178.000 33.91%
2019 -110.915.000 17.79%
2020 -169.836.000 34.69%
2021 -363.055.000 53.22%
2022 -368.118.000 1.38%
2023 -296.652.000 -24.09%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cantargia AB (publ) Gross Profit
Year Gross Profit Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cantargia AB (publ) Net Profit
Year Net Profit Growth
2011 -3.389.317
2012 -3.465.168 2.19%
2013 -7.945.937 56.39%
2014 -8.370.189 5.07%
2015 -17.190.000 51.31%
2016 -44.680.000 61.53%
2017 -60.253.000 25.85%
2018 -91.160.000 33.9%
2019 -110.691.000 17.64%
2020 -173.086.000 36.05%
2021 -366.507.000 52.77%
2022 -362.079.000 -1.22%
2023 -305.816.000 -18.4%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cantargia AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 -1 100%
2016 -2 50%
2017 -2 -100%
2018 -1 0%
2019 -1 0%
2020 -2 0%
2021 -4 66.67%
2022 -3 -50%
2023 -2 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cantargia AB (publ) Free Cashflow
Year Free Cashflow Growth
2011 -2.915.391
2012 -3.779.484 22.86%
2013 -8.262.486 54.26%
2014 6.221.572 232.8%
2015 -32.112.000 119.37%
2016 -42.338.000 24.15%
2017 -41.103.000 -3%
2018 -104.686.000 60.74%
2019 -118.134.000 11.38%
2020 -165.388.000 28.57%
2021 -346.828.000 52.31%
2022 -366.004.000 5.24%
2023 -85.667.000 -327.24%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cantargia AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2011 -2.915.391
2012 -3.779.484 22.86%
2013 -8.262.486 54.26%
2014 6.897.877 219.78%
2015 -30.277.000 122.78%
2016 -39.528.000 23.4%
2017 -41.103.000 3.83%
2018 -104.686.000 60.74%
2019 -111.254.000 5.9%
2020 -156.387.000 28.86%
2021 -346.445.000 54.86%
2022 -358.915.000 3.47%
2023 -85.667.000 -318.97%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cantargia AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2011 0
2012 0 0%
2013 0 0%
2014 676.305 100%
2015 1.835.000 63.14%
2016 2.810.000 34.7%
2017 0 0%
2018 0 0%
2019 6.880.000 100%
2020 9.001.000 23.56%
2021 383.000 -2250.13%
2022 7.089.000 94.6%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cantargia AB (publ) Equity
Year Equity Growth
2011 1.542.394
2012 3.077.186 49.88%
2013 3.131.689 1.74%
2014 4.097.426 23.57%
2015 28.055.000 85.4%
2016 37.127.000 24.44%
2017 246.120.000 84.92%
2018 155.045.000 -58.74%
2019 142.273.000 -8.98%
2020 891.935.000 84.05%
2021 532.745.000 -67.42%
2022 389.684.000 -36.71%
2023 184.184.000 -111.57%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cantargia AB (publ) Assets
Year Assets Growth
2011 2.403.665
2012 3.774.510 36.32%
2013 3.989.760 5.4%
2014 20.129.102 80.18%
2015 31.383.000 35.86%
2016 47.511.000 33.95%
2017 274.453.000 82.69%
2018 171.443.000 -60.08%
2019 166.057.000 -3.24%
2020 925.514.000 82.06%
2021 600.244.000 -54.19%
2022 474.798.000 -26.42%
2023 238.912.000 -98.73%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cantargia AB (publ) Liabilities
Year Liabilities Growth
2011 861.271
2012 697.324 -23.51%
2013 858.071 18.73%
2014 16.031.676 94.65%
2015 3.328.000 -381.72%
2016 10.384.000 67.95%
2017 28.333.000 63.35%
2018 16.398.000 -72.78%
2019 23.784.000 31.05%
2020 33.579.000 29.17%
2021 67.499.000 50.25%
2022 85.114.000 20.7%
2023 54.728.000 -55.52%

Cantargia AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-1.89
Price to Earning Ratio
-1.87x
Price To Sales Ratio
0x
POCF Ratio
-1.9
PFCF Ratio
-1.84
Price to Book Ratio
1.89
EV to Sales
0
EV Over EBITDA
-1.32
EV to Operating CashFlow
-1.39
EV to FreeCashFlow
-1.36
Earnings Yield
-0.54
FreeCashFlow Yield
-0.54
Market Cap
0,59 Bil.
Enterprise Value
0,43 Bil.
Graham Number
8.92
Graham NetNet
1.54

Income Statement Metrics

Net Income per Share
-1.89
Income Quality
0.93
ROE
-0.85
Return On Assets
-1.24
Return On Capital Employed
-1.72
Net Income per EBT
0.99
EBT Per Ebit
0.96
Ebit per Revenue
0
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.85
Free CashFlow per Share
-1.9
Capex to Operating CashFlow
0.02
Capex to Revenue
0
Capex to Depreciation
-1.92
Return on Invested Capital
-1.04
Return on Tangible Assets
-0.79
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.04

Balance Sheet

Cash per Share
2,09
Book Value per Share
1,87
Tangible Book Value per Share
1.84
Shareholders Equity per Share
1.87
Interest Debt per Share
0.02
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.47
Current Ratio
4.25
Tangible Asset Value
0,31 Bil.
Net Current Asset Value
0,30 Bil.
Invested Capital
0
Working Capital
0,30 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,00 Bil.
Average Payables
0,05 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cantargia AB (publ) Dividends
Year Dividends Growth

Cantargia AB (publ) Profile

About Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

CEO
Mr. Goran Forsberg
Employee
24
Address
Ideon Gateway
Lund, 223 63

Cantargia AB (publ) Executives & BODs

Cantargia AB (publ) Executives & BODs
# Name Age
1 Nina Valkama
Executive Assistant of Admin. & Fin.
70
2 Johanna Christensen
Financial Controller
70
3 Adnan Deronic
IP & Communications Mang.
70
4 Mr. Goran Forsberg
Chief Executive Officer
70
5 Mr. Marcus Järås
Founder & Scientific Advisor
70
6 Mr. Kjell Sjöström
Founder
70
7 Mr. Bengt Jondell
Chief Financial Officer
70
8 Ms. Liselotte Larsson
Chief Operating Officer
70
9 Dr. Dominique Tersago
Chief Medical Officer
70
10 Dr. David Liberg
Chief Scientific Officer
70
11 Mr. Thoas Fioretos M.D., Ph.D.
Founder & Scientific Advisor
70

Cantargia AB (publ) Competitors

Oncopeptides AB (publ) Logo
Oncopeptides AB (publ)

ONCO.ST

(1.0)
BioArctic AB (publ) Logo
BioArctic AB (publ)

BIOA-B.ST

(1.8)
Saniona AB (publ) Logo
Saniona AB (publ)

SANION.ST

(0.8)